Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profits of China's Pharmaceutical Industry Surge 50 Percent in Jan-Aug (China)

This article was originally published in PharmAsia News

Executive Summary

The China Pharmaceutical Industry Association announced profits for the country's drug production industry have reached $2.3 billion in the first eight months of 2008. That is a staggering 50.8 percent increase from last year's profits from the same time period. Despite the increased profits, many companies producing active pharmaceutical ingredients also reported bigger losses, mostly attributed to stricter export and environmental regulations. (Print Edition Only: Link to Full Text Unavailable

You may also be interested in...



US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare

Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.

US FDA Critic Leads House Appropriators, Consumer Health Ally Heads Energy And Commerce

Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.

CMS Final Medicare Outpatient Rule Gives Patients More Surgical Site Choices, At Lower Costs

The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel